In 2006, Takahashi and Yamakana published work showing that adult mouse cells could be reprogrammed into induced pluripotent stem (iPS) cells after the introduction of only four new genes1. Since then, the field of genetic reprogramming has advanced at an astonishing rate, producing over 1,000 published per year. In 2014, Japanese researchers reprogrammed skin cells from a 70 year old woman into retinal pigment epithelial cells2, marking the first clinical application of iPS cells in humans.
iPS cell reprogramming requires moving a cell backwards in its developmental pathway, to an immature, undifferentiated state. Once a cell has regained its pluripotent state, researchers can coax it down a new developmental pathway through manipulation of culture conditions. While there are still many aspects of cellular reprogramming that remain a mystery, researchers are rapidly closing in on the mysteries of cell fate determination.
iPS cells offer researchers a variety of new applications, from tissue replacement to drug development and toxicity screening. However, the process of reprogramming cells requires cell culture media that has consistent high quality from one lot to the next. Each lot of cell culture medium from MTI-GlobalStem® is rigorously tested to our PluriQ™ standards for quality, purity, and the effective maintenance of pluripotent stem cells over multiple passages to ensure culture health, morphology and lack of unwanted differentiation.
Each lot of PluriQ™ Medium undergoes testing for:
Our attention to detail during the manufacturing and QC process ensures consistent results, every time.
MTI-GlobalStem also offers highly efficicient transfection reagents. mRNA-In has be used to deliver RNA expressing pluripotency factors in order to establish induced pluripotent cell lines3 as described.
1Takahashi, K. & Yamanaka, S. Cell 126, 663–676 (2006).
2Cyranoski, D. Nature News May 2015 doi:10.1038/nature.2014.15915
3Kehler, J., Greco, M., Martino, V., Pachiappan, M., Yokoe, H., Chen, A., Yang, M., Jessee, J., Gotte, M., Milanesi, L., Albertini, A., Bellipanni, G., Zucchi, I., Reinbold, R. A. and Giordano, A. (2016), RNA-Generated and Gene-Edited Induced Pluripotent Stem Cells for Disease Modeling and Therapy. J. Cell. Physiol. 2016 Sep 15.